Merck KGaA: immunological compound tested against Covid
(CercleFinance.com) - The German group Merck KGaA announced on Thursday that it has started phase II clinical trials on a potential treatment for the most severe symptoms associated with Covid-19.
The pharmaceutical group said that the US Food and Drug Administration (FDA) has given it the green light to begin tests to assess the safety and efficacy of M5049, an immunological drug in development stages, in patients with the disease.
In particular, Merck says that it hopes to demonstrate a reduction in the immune response that causes the notorious "cytokine storm" that hits patients infected with Covid-19 who are affected by pneumonia.
The first results of the study are expected by the end of the year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The pharmaceutical group said that the US Food and Drug Administration (FDA) has given it the green light to begin tests to assess the safety and efficacy of M5049, an immunological drug in development stages, in patients with the disease.
In particular, Merck says that it hopes to demonstrate a reduction in the immune response that causes the notorious "cytokine storm" that hits patients infected with Covid-19 who are affected by pneumonia.
The first results of the study are expected by the end of the year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.